Ask AI

GPRC5D-Directed Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma: Clinical Evidence and Practice Implications

Start Activity
Text Module
Text Module Start Activity
This activity is available for 1.00 CME/CE credit(s).

Released: September 04, 2026

Expiration: March 03, 2027

See Activity Collection

Step 1 of 5

1 Pre Assessment 2 Text Module 3 Post Assessment 4 Evaluation 5 Credit

In this text module, an expert examines the evolving role of GPRC5D-directed bispecific antibodies in relapsed/refractory multiple myeloma, with a focus on evidence supporting bispecific antibodies and emerging CAR T-cell therapies across the treatment continuum. Learners will explore considerations for treatment selection and sequencing of GPRC5D-directed therapy in the current treatment landscape, emerging data for talquetamab-based strategies, and factors that may influence outcomes following prior targeted therapy. The activity also addresses practical approaches to GPRC5D-directed bispecific antibody dosing, toxicity prevention and management, and patient counseling to support safe and effective integration of talquetamab into clinical practice.

Ajai Chari
Ajai Chari, MD
GPRC5D BsAbs in RR MM

Pre Assessment

Assess your current knowledge and clinical approach before beginning your text module.
Begin Your Text Module
1.

How many people with MM do you provide care for in a typical week?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

A 78-year-old man with relapsed multiple myeloma (MM) was initially diagnosed with MM in 2015. He has now had 4 prior lines of therapy, including bortezomib/lenalidomide/dexamethasone followed by stem cell transplant and lenalidomide maintenance (5 years), followed by daratumumab/carfilzomib/dexamethasone (3 years), and then pomalidomide/cyclophosphamide/dexamethasone (1 year), followed by ciltacabtagene autoleucel (2 years ago). His PET/CT shows multiple sites of extramedullary disease. What would you recommend next?

4.

Your patient has elected to receive a bispecific antibody (BsAb) therapy that is delivered via subcutaneous administration (talquetamab, teclistamab, or elranatamab). You educate your patient on the approved BsAbs for MM that are administered subcutaneously and their unique adverse events (AEs). Which of the following AEs would you tell the patient occurs more commonly with GPRC5D-targeted BsAbs than with BCMA-targeted BsAbs?

5.

You have a patient with relapsed/refractory (R/R) MM who has become triple-class refractory and is skeptical about receiving another BsAb. What do you tell the patient about GPRC5D-directed BsAbs like talquetamab?

Begin Your Text Module